BACKGROUND Primary vaginal cancer is rare and most vaginal tumors are metastatic,often arising from adjacent gynecologic structures.Primary vaginal cancers are also more common among postmenopausal women and most of t...BACKGROUND Primary vaginal cancer is rare and most vaginal tumors are metastatic,often arising from adjacent gynecologic structures.Primary vaginal cancers are also more common among postmenopausal women and most of these are squamous cell carcinomas,with adenocarcinomas being relatively rare.Vaginal bleeding is the most common clinical manifestation of vaginal adenocarcinoma.About 70%of vaginal adenocarcinomas are stage I lesions at the time of diagnosis,for which radical surgery is recommended.However,more advanced vaginal cancers are not amenable to radical surgical treatment and have poor clinical outcomes.Optimal treatments modes are still being explored.Here,we report a rare case of stage IIb primary vaginal adenocarcinoma for which an individually designed vaginal applicator for after-loading radiotherapy was used to achieve good tumor control.CASE SUMMARY A 62-year-old woman presented to our clinic after 3 months of abnormal postmenopausal vaginal bleeding.Gynecological examination,computed tomography(CT),and positron emission tomography-CT showed a large mass(about 5 cm)on the anterior vaginal wall.Colposcopy biopsy confirmed adenocarcinoma of vaginal origin.After three cycles of carboplatin plus paclitaxel chemotherapy,the lesion partially shrunk.The patient then received external irradiation of 45 gray(gy)in 25 fractions,which further reduced the vaginal lesion,followed by after-loading radiotherapy of 30 gy in 5 fractions with an individually designed vaginal applicator.Three months later,magnetic resonance imaging showed a slight thickening CONCLUSION Primary vaginal adenocarcinoma is rare,and prognosis is poor in most vaginal cancers of locally advanced stages,which cannot be treated with radical surgery.Better tumor control can be achieved with an individualized vaginal applicator that allows administration of a higher radical dose to the tumor area while protecting normal tissues.展开更多
文摘BACKGROUND Primary vaginal cancer is rare and most vaginal tumors are metastatic,often arising from adjacent gynecologic structures.Primary vaginal cancers are also more common among postmenopausal women and most of these are squamous cell carcinomas,with adenocarcinomas being relatively rare.Vaginal bleeding is the most common clinical manifestation of vaginal adenocarcinoma.About 70%of vaginal adenocarcinomas are stage I lesions at the time of diagnosis,for which radical surgery is recommended.However,more advanced vaginal cancers are not amenable to radical surgical treatment and have poor clinical outcomes.Optimal treatments modes are still being explored.Here,we report a rare case of stage IIb primary vaginal adenocarcinoma for which an individually designed vaginal applicator for after-loading radiotherapy was used to achieve good tumor control.CASE SUMMARY A 62-year-old woman presented to our clinic after 3 months of abnormal postmenopausal vaginal bleeding.Gynecological examination,computed tomography(CT),and positron emission tomography-CT showed a large mass(about 5 cm)on the anterior vaginal wall.Colposcopy biopsy confirmed adenocarcinoma of vaginal origin.After three cycles of carboplatin plus paclitaxel chemotherapy,the lesion partially shrunk.The patient then received external irradiation of 45 gray(gy)in 25 fractions,which further reduced the vaginal lesion,followed by after-loading radiotherapy of 30 gy in 5 fractions with an individually designed vaginal applicator.Three months later,magnetic resonance imaging showed a slight thickening CONCLUSION Primary vaginal adenocarcinoma is rare,and prognosis is poor in most vaginal cancers of locally advanced stages,which cannot be treated with radical surgery.Better tumor control can be achieved with an individualized vaginal applicator that allows administration of a higher radical dose to the tumor area while protecting normal tissues.
文摘目的观察耳穴揿针联合栀黄散穴位贴敷对胆石症患者的应用效果。方法将120例患者随机分为A组:耳穴揿针组(40例),B组:穴位贴敷组(40例),C组:联合治疗组(40例)。A组患者在常规西医治疗的基础上加用耳穴揿针治疗,按压4~6次/d,1~3 min/次,5 d 1个疗程,双耳交替操作。B组患者在常规西医治疗的基础上加用栀黄散穴位贴敷,贴敷于双侧胆俞穴、双侧肝俞穴、右侧期门穴、双侧阳陵泉穴,贴敷时间为4~6 h,2次/d,5 d 1个疗程。C组患者在常规西医治疗的基础上联合使用耳穴揿针和栀黄散穴位贴敷治疗。通过疼痛数值评分量表(NRS)比较3组患者治疗后0.5、1、2、24、48 h疼痛评分;治疗前后3组患者C反应蛋白(C-reactive protein,CRP)、胆红素、肝功能(ALT)变化情况;通过B超检查治疗前后胆囊收缩功能、胆囊壁厚度。结果干预后3组患者疼痛评分时间效应值、CRP、胆红素、ALT数值、胆囊壁厚度均低于干预前,胆囊收缩功能较干预前增加,差异具有统计学意义(P<0.05),A组、B组两组患者干预后疼痛评分时间效应值、CRP、胆红素、ALT数值、胆囊壁厚度、胆囊收缩功能比较,差异无统计学意义(P>0.05)。C组患者干预后疼痛评分时间效应值、CRP、胆红素、ALT数值、胆囊壁厚度均低于A、B两组,胆囊收缩功能高于A、B两组,差异具有统计学意义(P<0.05)。结论耳穴揿针和栀黄散穴位贴敷应用于胆石症患者,均可减轻患者的疼痛反应,降低炎症作用,促进肝功能恢复,增强胆囊收缩功能。将两者联合应用,临床疗效更加显著,能够加速患者康复,值得临床推广。